These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25742468)

  • 1. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
    Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
    Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
    Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
    J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
    Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
    Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
    Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
    Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
    Zhang M; Xu E; Zhang J; Chen X
    Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    Kim B; Won D; Lee ST; Choi JR
    PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
    Ogasawara S; Kiyota Y; Chuman Y; Kowata A; Yoshimura F; Tanino K; Kamada R; Sakaguchi K
    Bioorg Med Chem; 2015 Oct; 23(19):6246-9. PubMed ID: 26358280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
    Ruark E; Snape K; Humburg P; Loveday C; Bajrami I; Brough R; Rodrigues DN; Renwick A; Seal S; Ramsay E; Duarte Sdel V; Rivas MA; Warren-Perry M; Zachariou A; Campion-Flora A; Hanks S; Murray A; Ansari Pour N; Douglas J; Gregory L; Rimmer A; Walker NM; Yang TP; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Eccles D; Evans DG; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; Gore M; Houlston R; Brown MA; Caufield MJ; Deloukas P; McCarthy MI; Todd JA; ; ; Turnbull C; Reis-Filho JS; Ashworth A; Antoniou AC; Lord CJ; Donnelly P; Rahman N
    Nature; 2013 Jan; 493(7432):406-10. PubMed ID: 23242139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
    Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
    Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
    Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
    Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.
    Lu X; Bocangel D; Nannenga B; Yamaguchi H; Appella E; Donehower LA
    Mol Cell; 2004 Aug; 15(4):621-34. PubMed ID: 15327777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
    Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
    Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.
    Burocziova M; Burdova K; Martinikova AS; Kasparek P; Kleiblova P; Danielsen SA; Borecka M; Jenikova G; Janečková L; Pavel J; Zemankova P; Schneiderova M; Schwarzova L; Ticha I; Sun XF; Jiraskova K; Liska V; Vodickova L; Vodicka P; Sedlacek R; Kleibl Z; Lothe RA; Korinek V; Macurek L
    Cell Death Dis; 2019 Oct; 10(11):818. PubMed ID: 31659152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites.
    Rossi M; Demidov ON; Anderson CW; Appella E; Mazur SJ
    Nucleic Acids Res; 2008 Dec; 36(22):7168-80. PubMed ID: 19015127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein phosphatase, Mg
    Husby S; Hjermind Justesen E; Grønbæk K
    Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.